BioMarin Acquires Amicus Therapeutics in $4.8 Billion Deal, Expanding Rare Disease Portfolio
BioMarin Pharmaceuticals has agreed to acquire Amicus Therapeutics for $4.8 billion in an all-cash transaction, valuing Amicus at $14.50 per share. The offer represents a 33% premium to Amicus' closing price on December 18, signaling strong strategic interest in the biotech firm's lysosomal storage disorder treatments.
TD Cowen downgraded Amicus stock from Buy to Hold following the announcement, aligning its price target with the acquisition offer. The deal bolsters BioMarin's rare disease pipeline with Galafold for Fabry disease and a promising Pompe disease therapy.
Amicus reported stronger-than-expected Q3 2025 results, with earnings of $0.06 per share surpassing estimates of $0.03. Revenue reached $169.1 million against projections of $165.4 million, demonstrating commercial traction for its therapies.
